Price Alert

Monte Rosa Therapeutics I... (GLUE)

NASDAQ: GLUE · Real-Time Price · USD

6.62

0.29 (4.58%)

At close: Sep 24, 2025, 3:59 PM

6.50

-1.81%

After-hours: Sep 24, 2025, 07:58 PM EDT

Monte Rosa Therapeutics Statistics

Share Statistics

Monte Rosa Therapeutics has 61.76M shares outstanding. The number of shares has increased by 0.22% in one year.

Shares Outstanding	61.76M
Shares Change (YoY)	0.22%
Shares Change (QoQ)	0%
Owned by Institutions (%)	72.46%
Shares Floating	46.18M
Failed to Deliver (FTD) Shares	59
FTD / Avg. Volume	0.01%

Short Selling Information

The latest short interest is 8.24M, so 13.34% of the outstanding shares have been sold short.

Short Interest	8.24M
Short % of Shares Out	13.34%
Short % of Float	17.67%
Short Ratio (days to cover)	24.99

Valuation Ratios

The PE ratio is -7.06 and the forward PE ratio is -4.69. Monte Rosa Therapeutics's PEG ratio is 0.11.

PE Ratio	-7.06
Forward PE	-4.69
PS Ratio	6.78
Forward PS	8.1
PB Ratio	2.3
P/FCF Ratio	13.5
PEG Ratio	0.11

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Monte Rosa Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.4, with a Debt / Equity ratio of 0.19.

Current Ratio	2.4
Quick Ratio	2.4
Debt / Equity	0.19
Debt / EBITDA	-0.59
Debt / FCF	1.12
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$532.55K
Profits Per Employee	$-511.97K
Employee Count	142
Asset Turnover	0.17
Inventory Turnover	n/a

Taxes

Income Tax	2.57M
Effective Tax Rate	-3.66%

Stock Price Statistics

The stock price has increased by 20.15% in the last 52 weeks. The beta is 1.42, so Monte Rosa Therapeutics's price volatility has been higher than the market average.

Beta	1.42
52-Week Price Change	20.15%
50-Day Moving Average	5.2
200-Day Moving Average	5.47
Relative Strength Index (RSI)	63.84
Average Volume (20 Days)	1,025,279

Income Statement

In the last 12 months, Monte Rosa Therapeutics had revenue of 75.62M and earned -72.7M in profits. Earnings per share was -0.98.

Revenue	75.62M
Gross Profit	67.5M
Operating Income	-81.11M
Net Income	-72.7M
EBITDA	-72.99M
EBIT	-81.11M
Earnings Per Share (EPS)	-0.98

Full Income Statement

Balance Sheet

The company has 224.25M in cash and 42.72M in debt, giving a net cash position of 181.54M.

Cash & Cash Equivalents	224.25M
Total Debt	42.72M
Net Cash	181.54M
Retained Earnings	-438.59M
Total Assets	359.59M
Working Capital	257.61M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 42M and capital expenditures -3.99M, giving a free cash flow of 38.01M.

Operating Cash Flow	42M
Capital Expenditures	-3.99M
Free Cash Flow	38.01M
FCF Per Share	0.51

Full Cash Flow Statement

Margins

Gross margin is 89.26%, with operating and profit margins of -107.26% and -96.14%.

Gross Margin	89.26%
Operating Margin	-107.26%
Pretax Margin	-92.74%
Profit Margin	-96.14%
EBITDA Margin	-96.52%
EBIT Margin	-107.26%
FCF Margin	50.26%

Dividends & Yields

GLUE does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for GLUE is $13.5, which is 103.9% higher than the current price. The consensus rating is "Hold".

Price Target	$13.5
Price Target Difference	103.9%
Analyst Consensus	Hold
Analyst Count	2

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	1.86
Piotroski F-Score	7